Investment Letter
Issue 112 — 🔬 Fantastic Voyage, For Real: Nanorobotics, DNA Origami, and the Tiny Machines Already in Human Trials
Nanorobotics market estimated $5-10B 2024-25 across independent research firms, growing toward $13-17B by 2030-34. Two mechanisms: magnetic micro-robots (gradient pulling vs rotating-field corkscrew propulsion, MRI-compatible external steering, fluoroscopy/ultrasound/MPI real-time tracking) and DNA origami (scaffold + staple strand self-assembly, container/lock/deployment architecture, up to 50,000 drug molecules per structure, 90% targeting efficiency). DNA synthesis cost collapsed to ~$0.01/test via $19,900 open-source synthesizers — Moore's Law-style cost curve. Karolinska Institute: 70% tumour growth reduction in mice, July 2024, mechanism generalizes across breast/melanoma/ovarian/lung cancer models. Companies: Bionaut Labs (2 FDA designations — Orphan Drug for BNL-101 gliomas, Humanitarian Use Device for BNL-201 Dandy-Walker Syndrome; $63.2M raised; Khosla Ventures/Mayo Clinic/Gates Ventures; Candel Therapeutics oncolytic virus partnership), Robeauté ($28M raised Jan 2025, targeting 2026 human trials — critical second-mover validation), Theranautilus (IISc spin-off, India, dental application, faster regulatory path), Nanobots Therapeutics (Spain, gas-propelled MotionTx platform, clinical-stage). Infrastructure layer: Bruker, JEOL, Thermo Fisher, Oxford Instruments, ZEISS — the picks-and-shovels equipment makers, same logic as nuclear fuel (105) and semiconductors (97). Honest caveats: regulators favor passive nanomedicines over active autonomous robots, market sizing wildly inconsistent across research firms, manufacturing scalability unresolved. — Pawan Bhatia